EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Natural Compound α‐Hederin via Large‐Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy

Jiayu Wang, Pengzhan He, Cheng Liu, Xin Chen, Yilin Tan, Rui Qu, Yan Zhang, Zhou Li, Tailang Yin, Zhinang Yin iD

Advanced Science · 2025

DOI: 10.1002/advs.202417278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiayu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ovarian Neoplasms, Oleanolic Acid, Janus Kinase 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance and metastasis are key obstacles to successful ovarian cancer (OC) treatment. Here, α‐Hederin, a pentacyclic triterpenoid saponin, is identified as a potent and selective dual inhibitor of JAK1/JAK2 with promising therapeutic potential in OC. Integrating transcriptomic analysis, virtual screening, molecular docking, and biochemical validation, it is shown that α‐Hederin directly binds the JH1 kinase domains of JAK1 and JAK2, suppressing their activity and downstream STAT3 phosphorylation. α‐Hederin inhibits OC cell proliferation, epithelial‐mesenchymal transition (EMT), and metastasis in vitro, and suppresses tumor growth and dissemination in multiple mouse models, with minimal systemic toxicity. Mechanistically, α‐Hederin blocks STAT3 nuclear translocation and downregulates oncogenic STAT3 targets including MYC, CCND1, and TWIST1. Rescue experiments using the STAT3 agonist Colivelin partially reversed these effects, confirming the JAK/STAT3 axis as a key target. Moreover, α‐Hederin synergizes with cisplatin to enhance antitumor efficacy and overcomes platinum resistance in OC cells. Collectively, our findings highlight α‐Hederin as a safe and effective natural JAK1/2 inhibitor that suppresses OC progression by targeting the JAK/STAT3 pathway, offering a compelling candidate for future clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorOvarian NeoplasmsOleanolic AcidJanus Kinase 2SaponinsFemaleHumansAnimalsMiceCell Line, TumorCell ProliferationJanus Kinase 1Epithelial-Mesenchymal TransitionAntineoplastic AgentsSignal TransductionDrug Discovery

Stichwörter der Autor:innen

JAKmetastasisovarian cancerproliferationα‐Hederin

Substanzen

STAT3 Transcription FactorOleanolic AcidSTAT3 protein, humanJanus Kinase 2SaponinsJanus Kinase 1Antineoplastic AgentsJAK1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
  • Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
  • Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
  • Reproductive Medical Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
  • School of Nanoscience and Engineering, University of Chinese Academy of Sciences, Beijing, 101400, China.

ORCID-Profile: Zhinang Yin

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Hubei Province
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Wang, J., He, P., Liu, C., Chen, X., Tan, Y., Qu, R., Zhang, Y., Li, Z., Yin, T., & Yin, Z. (2025). Discovery of Natural Compound α‐Hederin via Large‐Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202417278

Vancouver

Wang J, He P, Liu C, Chen X, Tan Y, Qu R, et al. Discovery of Natural Compound α‐Hederin via Large‐Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy. Advanced Science. 2025. doi:10.1002/advs.202417278

BibTeX
@article{Wang2025,
  author = {Wang, Jiayu and He, Pengzhan and Liu, Cheng and Chen, Xin and Tan, Yilin and Qu, Rui and Zhang, Yan and Li, Zhou and Yin, Tailang and Yin, Zhinang},
  title = {Discovery of Natural Compound α‐Hederin via Large‐Scale Screening as a Targeted JAK/STAT3 Inhibitor for Ovarian Cancer Therapy},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202417278}
}
Kostenlos starten →